| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 82 | 2024 | 547 | 7.610 |
Why?
|
| Coronary Angiography | 43 | 2024 | 324 | 4.110 |
Why?
|
| Myocardial Infarction | 49 | 2023 | 1211 | 3.260 |
Why?
|
| Registries | 72 | 2024 | 2398 | 2.990 |
Why?
|
| Transcatheter Aortic Valve Replacement | 12 | 2025 | 153 | 2.610 |
Why?
|
| Coronary Artery Disease | 29 | 2024 | 743 | 2.560 |
Why?
|
| Aortic Valve Stenosis | 12 | 2024 | 255 | 2.220 |
Why?
|
| Cardiac Catheterization | 25 | 2024 | 561 | 2.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 25 | 2014 | 158 | 2.000 |
Why?
|
| Cardiology | 12 | 2022 | 358 | 1.420 |
Why?
|
| Radial Artery | 17 | 2022 | 70 | 1.370 |
Why?
|
| Hemorrhage | 23 | 2024 | 810 | 1.320 |
Why?
|
| Hospital Mortality | 30 | 2024 | 1035 | 1.160 |
Why?
|
| Drug-Eluting Stents | 13 | 2019 | 88 | 1.140 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 2182 | 1.110 |
Why?
|
| Acute Coronary Syndrome | 11 | 2024 | 295 | 1.070 |
Why?
|
| Femoral Artery | 14 | 2022 | 190 | 0.990 |
Why?
|
| Ultrasonography, Interventional | 7 | 2015 | 161 | 0.960 |
Why?
|
| Platelet Aggregation Inhibitors | 14 | 2019 | 498 | 0.930 |
Why?
|
| Treatment Outcome | 80 | 2025 | 11731 | 0.920 |
Why?
|
| Heart Valve Prosthesis | 4 | 2021 | 134 | 0.910 |
Why?
|
| Aged | 123 | 2025 | 26001 | 0.900 |
Why?
|
| Contrast Media | 9 | 2024 | 491 | 0.880 |
Why?
|
| Ticlopidine | 7 | 2016 | 54 | 0.870 |
Why?
|
| United States | 86 | 2024 | 16051 | 0.860 |
Why?
|
| Pacemaker, Artificial | 19 | 2018 | 126 | 0.820 |
Why?
|
| Aortic Valve | 9 | 2024 | 366 | 0.810 |
Why?
|
| Coronary Stenosis | 8 | 2014 | 38 | 0.790 |
Why?
|
| Influenza Pandemic, 1918-1919 | 1 | 2023 | 1 | 0.790 |
Why?
|
| Coronary Artery Bypass | 11 | 2021 | 270 | 0.780 |
Why?
|
| Postoperative Complications | 14 | 2025 | 2938 | 0.780 |
Why?
|
| Imaging, Three-Dimensional | 13 | 2016 | 586 | 0.750 |
Why?
|
| Catheterization, Peripheral | 7 | 2022 | 119 | 0.740 |
Why?
|
| Coronary Vessels | 13 | 2019 | 254 | 0.730 |
Why?
|
| Humans | 209 | 2025 | 145305 | 0.710 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 7 | 2019 | 70 | 0.710 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2023 | 157 | 0.690 |
Why?
|
| Risk Factors | 49 | 2024 | 10816 | 0.680 |
Why?
|
| Shock, Cardiogenic | 10 | 2023 | 64 | 0.680 |
Why?
|
| Stents | 15 | 2016 | 557 | 0.680 |
Why?
|
| Electrocardiography | 21 | 2020 | 663 | 0.650 |
Why?
|
| Time Factors | 38 | 2024 | 7186 | 0.640 |
Why?
|
| Acute Kidney Injury | 5 | 2024 | 870 | 0.630 |
Why?
|
| Computer Simulation | 7 | 2014 | 1026 | 0.610 |
Why?
|
| Hospitals | 10 | 2022 | 733 | 0.610 |
Why?
|
| Middle Aged | 100 | 2024 | 36021 | 0.600 |
Why?
|
| Male | 137 | 2025 | 72628 | 0.580 |
Why?
|
| Radiography, Interventional | 8 | 2019 | 130 | 0.580 |
Why?
|
| Coronary Disease | 10 | 2012 | 386 | 0.570 |
Why?
|
| Risk Assessment | 26 | 2024 | 3686 | 0.570 |
Why?
|
| Female | 136 | 2025 | 78605 | 0.570 |
Why?
|
| Coronary Restenosis | 3 | 2013 | 22 | 0.550 |
Why?
|
| ST Elevation Myocardial Infarction | 4 | 2023 | 64 | 0.520 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2013 | 9 | 0.490 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2019 | 71 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 10 | 2019 | 1358 | 0.480 |
Why?
|
| Myocardial Ischemia | 6 | 2013 | 286 | 0.470 |
Why?
|
| Models, Cardiovascular | 3 | 2013 | 195 | 0.470 |
Why?
|
| Hospitals, High-Volume | 6 | 2021 | 50 | 0.470 |
Why?
|
| Cardiac Pacing, Artificial | 13 | 2007 | 84 | 0.470 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2019 | 42 | 0.460 |
Why?
|
| Follow-Up Studies | 29 | 2021 | 5431 | 0.460 |
Why?
|
| Aged, 80 and over | 39 | 2025 | 8295 | 0.450 |
Why?
|
| Hospitals, Low-Volume | 5 | 2021 | 26 | 0.450 |
Why?
|
| Endovascular Procedures | 4 | 2025 | 385 | 0.450 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 9 | 2019 | 122 | 0.430 |
Why?
|
| Allografts | 1 | 2015 | 150 | 0.430 |
Why?
|
| Prasugrel Hydrochloride | 5 | 2016 | 22 | 0.420 |
Why?
|
| Medicare | 12 | 2021 | 890 | 0.420 |
Why?
|
| Fluoroscopy | 7 | 2021 | 176 | 0.420 |
Why?
|
| Patient Readmission | 7 | 2024 | 760 | 0.420 |
Why?
|
| Survival Rate | 12 | 2021 | 2100 | 0.420 |
Why?
|
| Intra-Aortic Balloon Pumping | 4 | 2021 | 19 | 0.420 |
Why?
|
| Vascular Diseases | 2 | 2015 | 252 | 0.400 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 71 | 0.390 |
Why?
|
| Heart Arrest | 4 | 2021 | 407 | 0.380 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 245 | 0.380 |
Why?
|
| Postoperative Hemorrhage | 4 | 2016 | 104 | 0.370 |
Why?
|
| Quality Indicators, Health Care | 5 | 2021 | 336 | 0.370 |
Why?
|
| Retrospective Studies | 40 | 2025 | 17149 | 0.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2024 | 199 | 0.370 |
Why?
|
| Coronary Thrombosis | 2 | 2012 | 25 | 0.370 |
Why?
|
| Heart-Assist Devices | 4 | 2023 | 569 | 0.360 |
Why?
|
| Length of Stay | 7 | 2024 | 1342 | 0.360 |
Why?
|
| Heart Defects, Congenital | 4 | 2021 | 916 | 0.350 |
Why?
|
| Patient Discharge | 6 | 2024 | 987 | 0.340 |
Why?
|
| Decision Support Techniques | 6 | 2024 | 460 | 0.340 |
Why?
|
| Heart Failure | 3 | 2023 | 2331 | 0.340 |
Why?
|
| Teaching | 1 | 2013 | 240 | 0.330 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2024 | 124 | 0.330 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 386 | 0.330 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 380 | 0.330 |
Why?
|
| Coronary Aneurysm | 1 | 2010 | 17 | 0.320 |
Why?
|
| Heart Block | 8 | 2018 | 40 | 0.320 |
Why?
|
| Embolic Protection Devices | 2 | 2024 | 12 | 0.320 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2021 | 134 | 0.310 |
Why?
|
| Hemostatic Techniques | 3 | 2020 | 51 | 0.300 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2023 | 361 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1568 | 0.300 |
Why?
|
| Peptide Fragments | 6 | 2020 | 699 | 0.300 |
Why?
|
| Anticoagulants | 6 | 2015 | 726 | 0.300 |
Why?
|
| Clinical Competence | 7 | 2017 | 1247 | 0.290 |
Why?
|
| Image Enhancement | 2 | 2010 | 200 | 0.290 |
Why?
|
| Heart Transplantation | 1 | 2015 | 738 | 0.290 |
Why?
|
| Predictive Value of Tests | 16 | 2020 | 2118 | 0.280 |
Why?
|
| Radiation Dosage | 7 | 2016 | 193 | 0.280 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 560 | 0.280 |
Why?
|
| Databases, Factual | 6 | 2024 | 1488 | 0.280 |
Why?
|
| Cardiology Service, Hospital | 2 | 2020 | 29 | 0.270 |
Why?
|
| Hirudins | 6 | 2020 | 51 | 0.270 |
Why?
|
| Veterans | 2 | 2019 | 1615 | 0.260 |
Why?
|
| Patient Simulation | 1 | 2008 | 41 | 0.260 |
Why?
|
| Myocardial Revascularization | 6 | 2016 | 85 | 0.260 |
Why?
|
| Angioplasty | 2 | 2010 | 50 | 0.260 |
Why?
|
| Prospective Studies | 22 | 2024 | 8011 | 0.260 |
Why?
|
| Incidence | 12 | 2020 | 2892 | 0.250 |
Why?
|
| Device Removal | 3 | 2005 | 143 | 0.240 |
Why?
|
| Defibrillators, Implantable | 3 | 2022 | 382 | 0.240 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 299 | 0.240 |
Why?
|
| Quality Improvement | 5 | 2019 | 1296 | 0.240 |
Why?
|
| Workload | 2 | 2019 | 170 | 0.240 |
Why?
|
| Societies, Medical | 4 | 2020 | 893 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 411 | 0.230 |
Why?
|
| Pandemics | 4 | 2023 | 1698 | 0.230 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2019 | 64 | 0.230 |
Why?
|
| Antithrombins | 4 | 2020 | 70 | 0.230 |
Why?
|
| Drug Substitution | 2 | 2016 | 63 | 0.220 |
Why?
|
| Consensus | 4 | 2020 | 476 | 0.220 |
Why?
|
| Prognosis | 8 | 2024 | 4310 | 0.220 |
Why?
|
| Advisory Committees | 2 | 2020 | 230 | 0.220 |
Why?
|
| Radiographic Image Enhancement | 3 | 2006 | 57 | 0.220 |
Why?
|
| Comorbidity | 8 | 2019 | 1661 | 0.220 |
Why?
|
| Propensity Score | 7 | 2020 | 370 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1747 | 0.220 |
Why?
|
| Odds Ratio | 10 | 2017 | 1077 | 0.220 |
Why?
|
| American Heart Association | 3 | 2016 | 356 | 0.220 |
Why?
|
| Heart Septum | 2 | 2015 | 28 | 0.210 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2019 | 104 | 0.210 |
Why?
|
| Education, Medical | 1 | 2008 | 276 | 0.210 |
Why?
|
| Angiography | 4 | 2021 | 208 | 0.210 |
Why?
|
| Cardiologists | 2 | 2021 | 47 | 0.210 |
Why?
|
| Thrombolytic Therapy | 3 | 2020 | 163 | 0.210 |
Why?
|
| Learning Curve | 2 | 2015 | 70 | 0.210 |
Why?
|
| Comparative Effectiveness Research | 6 | 2016 | 170 | 0.200 |
Why?
|
| Vascular Fistula | 1 | 2024 | 22 | 0.200 |
Why?
|
| Heart Diseases | 3 | 2019 | 350 | 0.200 |
Why?
|
| Kidney Diseases | 2 | 2023 | 427 | 0.200 |
Why?
|
| Aspirin | 3 | 2015 | 401 | 0.200 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 96 | 0.200 |
Why?
|
| Algorithms | 8 | 2020 | 1846 | 0.200 |
Why?
|
| Certification | 2 | 2015 | 121 | 0.190 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2015 | 145 | 0.190 |
Why?
|
| Aorta, Thoracic | 1 | 2025 | 286 | 0.190 |
Why?
|
| Stroke | 7 | 2024 | 1260 | 0.190 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 736 | 0.190 |
Why?
|
| Betacoronavirus | 3 | 2020 | 285 | 0.190 |
Why?
|
| Cineangiography | 5 | 2009 | 9 | 0.190 |
Why?
|
| Myocardial Reperfusion | 2 | 2013 | 60 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2013 | 1261 | 0.190 |
Why?
|
| Heart Injuries | 1 | 2023 | 42 | 0.190 |
Why?
|
| Research Design | 3 | 2022 | 1137 | 0.190 |
Why?
|
| Intraoperative Care | 2 | 2013 | 62 | 0.190 |
Why?
|
| Age Factors | 9 | 2020 | 3339 | 0.180 |
Why?
|
| Heart Ventricles | 6 | 2018 | 762 | 0.180 |
Why?
|
| Severity of Illness Index | 12 | 2020 | 2926 | 0.180 |
Why?
|
| Enoxaparin | 2 | 2015 | 67 | 0.180 |
Why?
|
| History, 20th Century | 1 | 2023 | 327 | 0.180 |
Why?
|
| Technology Transfer | 1 | 2021 | 9 | 0.170 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 129 | 0.170 |
Why?
|
| Sex Factors | 5 | 2014 | 2115 | 0.170 |
Why?
|
| Forecasting | 2 | 2022 | 392 | 0.170 |
Why?
|
| Guideline Adherence | 3 | 2015 | 589 | 0.170 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 3419 | 0.170 |
Why?
|
| Inpatients | 2 | 2024 | 551 | 0.170 |
Why?
|
| Physicians | 3 | 2015 | 950 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 2 | 2024 | 181 | 0.160 |
Why?
|
| Retreatment | 3 | 2019 | 77 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2019 | 656 | 0.160 |
Why?
|
| Surgicenters | 1 | 2020 | 5 | 0.160 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2464 | 0.160 |
Why?
|
| Ischemia | 3 | 2009 | 421 | 0.160 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 2959 | 0.160 |
Why?
|
| Saphenous Vein | 3 | 2015 | 37 | 0.160 |
Why?
|
| Septal Occluder Device | 2 | 2018 | 37 | 0.160 |
Why?
|
| Manuals as Topic | 1 | 2020 | 16 | 0.160 |
Why?
|
| Proportional Hazards Models | 8 | 2016 | 1328 | 0.160 |
Why?
|
| Assisted Circulation | 2 | 2021 | 26 | 0.150 |
Why?
|
| Ethanol | 2 | 2015 | 627 | 0.150 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 529 | 0.150 |
Why?
|
| Thrombosis | 3 | 2016 | 398 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 385 | 0.150 |
Why?
|
| Absorbable Implants | 1 | 2019 | 37 | 0.150 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2019 | 38 | 0.140 |
Why?
|
| Popliteal Artery | 2 | 2009 | 62 | 0.140 |
Why?
|
| Logistic Models | 8 | 2017 | 2119 | 0.140 |
Why?
|
| Rural Health Services | 1 | 2020 | 141 | 0.140 |
Why?
|
| Angina Pectoris | 1 | 2019 | 75 | 0.140 |
Why?
|
| Electrodes, Implanted | 5 | 1999 | 115 | 0.140 |
Why?
|
| Atrioventricular Block | 1 | 2019 | 45 | 0.140 |
Why?
|
| Infection Control | 1 | 2020 | 173 | 0.140 |
Why?
|
| Medicaid | 2 | 2013 | 466 | 0.140 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 77 | 0.140 |
Why?
|
| Models, Anatomic | 2 | 2009 | 87 | 0.140 |
Why?
|
| Recombinant Proteins | 8 | 2020 | 1371 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2015 | 782 | 0.140 |
Why?
|
| Health Care Costs | 2 | 2019 | 427 | 0.140 |
Why?
|
| Myocardium | 1 | 2023 | 940 | 0.130 |
Why?
|
| Quality of Health Care | 2 | 2016 | 696 | 0.130 |
Why?
|
| Creatinine | 4 | 2024 | 510 | 0.130 |
Why?
|
| Rotation | 5 | 2011 | 121 | 0.130 |
Why?
|
| Subacute Care | 1 | 2018 | 82 | 0.130 |
Why?
|
| Cohort Studies | 11 | 2023 | 5982 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 140 | 0.130 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2016 | 10 | 0.130 |
Why?
|
| Tissue Scaffolds | 1 | 2019 | 223 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 3 | 2009 | 340 | 0.120 |
Why?
|
| Atrial Fibrillation | 3 | 2007 | 552 | 0.120 |
Why?
|
| Leg | 2 | 2009 | 239 | 0.120 |
Why?
|
| Angioplasty, Balloon | 2 | 2007 | 94 | 0.120 |
Why?
|
| Aortography | 1 | 2016 | 52 | 0.120 |
Why?
|
| Equipment Design | 7 | 2014 | 530 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 40 | 0.120 |
Why?
|
| Long Term Adverse Effects | 1 | 2015 | 13 | 0.120 |
Why?
|
| Heart Valve Diseases | 2 | 2015 | 151 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 1048 | 0.120 |
Why?
|
| Syncope | 1 | 2016 | 55 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 109 | 0.110 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2015 | 43 | 0.110 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 112 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 54 | 0.110 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2015 | 4 | 0.110 |
Why?
|
| Metals | 1 | 2016 | 142 | 0.110 |
Why?
|
| Education, Medical, Continuing | 2 | 2013 | 132 | 0.110 |
Why?
|
| Injections | 3 | 2014 | 197 | 0.110 |
Why?
|
| Vascular Grafting | 1 | 2015 | 15 | 0.110 |
Why?
|
| Punctures | 3 | 2020 | 40 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2015 | 36 | 0.110 |
Why?
|
| Elective Surgical Procedures | 2 | 2013 | 201 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 146 | 0.110 |
Why?
|
| Platelet Activation | 1 | 2015 | 104 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 494 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2015 | 59 | 0.110 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 947 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 2 | 2020 | 340 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2015 | 151 | 0.100 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2014 | 64 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2018 | 353 | 0.100 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2013 | 6 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 173 | 0.100 |
Why?
|
| Thrombectomy | 2 | 2012 | 78 | 0.100 |
Why?
|
| Prosthesis Design | 2 | 2013 | 357 | 0.100 |
Why?
|
| Clinical Decision-Making | 3 | 2024 | 360 | 0.100 |
Why?
|
| Warfarin | 1 | 2015 | 171 | 0.100 |
Why?
|
| Academies and Institutes | 1 | 2013 | 60 | 0.100 |
Why?
|
| Radiation | 1 | 2013 | 24 | 0.100 |
Why?
|
| Withholding Treatment | 1 | 2014 | 81 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2006 | 140 | 0.100 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 27 | 0.100 |
Why?
|
| Renal Dialysis | 3 | 2014 | 465 | 0.100 |
Why?
|
| Cardiac Volume | 2 | 2003 | 15 | 0.100 |
Why?
|
| Heparin | 2 | 2015 | 244 | 0.100 |
Why?
|
| Patient Selection | 5 | 2019 | 726 | 0.090 |
Why?
|
| Coronary Occlusion | 1 | 2012 | 20 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 266 | 0.090 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2012 | 16 | 0.090 |
Why?
|
| Wound Closure Techniques | 1 | 2012 | 13 | 0.090 |
Why?
|
| Fibrinolytic Agents | 2 | 2009 | 293 | 0.090 |
Why?
|
| Medical Audit | 1 | 2012 | 77 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1500 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2016 | 541 | 0.090 |
Why?
|
| Adult | 19 | 2015 | 40627 | 0.090 |
Why?
|
| Aneurysm, False | 1 | 2012 | 45 | 0.090 |
Why?
|
| Embolism | 1 | 2012 | 48 | 0.090 |
Why?
|
| Angina, Unstable | 1 | 2012 | 82 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 1104 | 0.090 |
Why?
|
| Triiodobenzoic Acids | 2 | 2011 | 6 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2015 | 400 | 0.090 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2012 | 84 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 83 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 1 | 2013 | 272 | 0.090 |
Why?
|
| Quality of Life | 5 | 2019 | 3197 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2016 | 603 | 0.080 |
Why?
|
| Polyethylene Terephthalates | 1 | 1991 | 21 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 342 | 0.080 |
Why?
|
| Phantoms, Imaging | 2 | 2002 | 158 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 541 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 772 | 0.080 |
Why?
|
| Manikins | 1 | 2010 | 35 | 0.080 |
Why?
|
| Movement | 2 | 2009 | 296 | 0.080 |
Why?
|
| Cardiovascular Agents | 4 | 2016 | 165 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 967 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 1992 | 0.080 |
Why?
|
| Observer Variation | 3 | 2011 | 355 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 1540 | 0.070 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2009 | 38 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 3 | 2023 | 764 | 0.070 |
Why?
|
| Prosthesis Failure | 1 | 2010 | 128 | 0.070 |
Why?
|
| Recurrence | 4 | 2016 | 1138 | 0.070 |
Why?
|
| Equipment Failure | 2 | 2005 | 115 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 783 | 0.070 |
Why?
|
| Cause of Death | 3 | 2020 | 474 | 0.070 |
Why?
|
| Prevalence | 5 | 2019 | 2838 | 0.070 |
Why?
|
| Vascular Closure Devices | 2 | 2020 | 6 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2015 | 827 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 102 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2021 | 149 | 0.070 |
Why?
|
| Hyperbaric Oxygenation | 2 | 1998 | 39 | 0.070 |
Why?
|
| Heart Atria | 6 | 1990 | 144 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 2328 | 0.070 |
Why?
|
| Aftercare | 2 | 2022 | 224 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2010 | 242 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2007 | 54 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2009 | 251 | 0.060 |
Why?
|
| Extremities | 1 | 2007 | 140 | 0.060 |
Why?
|
| Stroke Volume | 5 | 2015 | 653 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 2745 | 0.060 |
Why?
|
| Tuberculosis, Spinal | 1 | 2006 | 8 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1998 | 244 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2013 | 1386 | 0.060 |
Why?
|
| Mortality | 3 | 2016 | 376 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 98 | 0.060 |
Why?
|
| Hemodynamics | 3 | 2020 | 1122 | 0.060 |
Why?
|
| Systole | 2 | 1983 | 178 | 0.060 |
Why?
|
| Biomarkers | 4 | 2023 | 4284 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2009 | 438 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 77 | 0.050 |
Why?
|
| Vascular Patency | 3 | 2012 | 121 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 5883 | 0.050 |
Why?
|
| Sirolimus | 1 | 2006 | 281 | 0.050 |
Why?
|
| Prosthesis Implantation | 1 | 2006 | 153 | 0.050 |
Why?
|
| Intraoperative Complications | 2 | 2018 | 158 | 0.050 |
Why?
|
| Equipment Safety | 1 | 2004 | 38 | 0.050 |
Why?
|
| Patient Safety | 2 | 2020 | 349 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2024 | 64 | 0.050 |
Why?
|
| Intracranial Embolism | 1 | 2024 | 34 | 0.050 |
Why?
|
| Risk | 3 | 2012 | 912 | 0.050 |
Why?
|
| Protective Factors | 1 | 2024 | 99 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2005 | 128 | 0.050 |
Why?
|
| Adenosine | 2 | 2016 | 255 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1098 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2005 | 99 | 0.050 |
Why?
|
| Peptides | 1 | 2009 | 999 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 205 | 0.050 |
Why?
|
| Reoperation | 2 | 2021 | 631 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2004 | 228 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 49 | 0.050 |
Why?
|
| Catheters | 1 | 2023 | 75 | 0.050 |
Why?
|
| Patient Preference | 2 | 2016 | 226 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2024 | 310 | 0.050 |
Why?
|
| Pyridines | 1 | 2006 | 605 | 0.040 |
Why?
|
| Risk Adjustment | 2 | 2013 | 85 | 0.040 |
Why?
|
| Kidney | 2 | 2023 | 1499 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2021 | 35 | 0.040 |
Why?
|
| Physical Exertion | 1 | 1982 | 207 | 0.040 |
Why?
|
| Patient Participation | 1 | 2024 | 433 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 1982 | 298 | 0.040 |
Why?
|
| Endocardium | 2 | 1990 | 31 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2019 | 220 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 119 | 0.040 |
Why?
|
| Curriculum | 1 | 2008 | 1072 | 0.040 |
Why?
|
| Mass Screening | 1 | 2009 | 1357 | 0.040 |
Why?
|
| Pressure | 2 | 2012 | 225 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 114 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 117 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2020 | 37 | 0.040 |
Why?
|
| Population Density | 1 | 2020 | 101 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 147 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 226 | 0.040 |
Why?
|
| Tachycardia, Supraventricular | 2 | 1990 | 45 | 0.040 |
Why?
|
| Heart Rate | 4 | 2011 | 857 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2003 | 393 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 120 | 0.040 |
Why?
|
| Device Approval | 1 | 2019 | 19 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 1268 | 0.040 |
Why?
|
| Travel | 1 | 2020 | 136 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2014 | 682 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 31 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 176 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2019 | 45 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2019 | 144 | 0.040 |
Why?
|
| Writing | 1 | 2020 | 103 | 0.030 |
Why?
|
| Colorado | 3 | 2019 | 4579 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 639 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 1997 | 7 | 0.030 |
Why?
|
| Data Collection | 1 | 2020 | 635 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 1136 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2020 | 378 | 0.030 |
Why?
|
| Exercise Test | 3 | 2014 | 635 | 0.030 |
Why?
|
| Social Media | 1 | 2020 | 171 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2016 | 84 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 647 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 737 | 0.030 |
Why?
|
| Radiologic Health | 1 | 2015 | 4 | 0.030 |
Why?
|
| Automation | 1 | 2016 | 102 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 82 | 0.030 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2015 | 44 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2015 | 34 | 0.030 |
Why?
|
| Radiation Exposure | 1 | 2016 | 63 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 137 | 0.030 |
Why?
|
| Drug Costs | 1 | 2016 | 116 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2016 | 194 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2007 | 319 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 18 | 0.030 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2015 | 40 | 0.030 |
Why?
|
| Thrombelastography | 1 | 2015 | 178 | 0.030 |
Why?
|
| Radiology, Interventional | 1 | 1994 | 49 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 29 | 0.030 |
Why?
|
| Angina, Stable | 1 | 2014 | 18 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 124 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 218 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 282 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 49 | 0.030 |
Why?
|
| Virginia | 1 | 2013 | 55 | 0.030 |
Why?
|
| Atrial Function | 2 | 1990 | 10 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1063 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2013 | 166 | 0.020 |
Why?
|
| Solvents | 1 | 2014 | 113 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 103 | 0.020 |
Why?
|
| Professional Competence | 1 | 2014 | 98 | 0.020 |
Why?
|
| Echocardiography | 2 | 2014 | 656 | 0.020 |
Why?
|
| Foundations | 1 | 2013 | 27 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2011 | 1771 | 0.020 |
Why?
|
| Cladribine | 1 | 1993 | 1 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 848 | 0.020 |
Why?
|
| Sinoatrial Node | 2 | 1990 | 27 | 0.020 |
Why?
|
| Canada | 1 | 2014 | 429 | 0.020 |
Why?
|
| Research Report | 1 | 2013 | 87 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 286 | 0.020 |
Why?
|
| Telemetry | 2 | 1989 | 41 | 0.020 |
Why?
|
| Observation | 1 | 2012 | 54 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 854 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 333 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 284 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 124 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 2032 | 0.020 |
Why?
|
| Posture | 2 | 2009 | 196 | 0.020 |
Why?
|
| Pectoralis Muscles | 1 | 1991 | 17 | 0.020 |
Why?
|
| Esthetics | 1 | 1991 | 41 | 0.020 |
Why?
|
| Software | 1 | 2016 | 692 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 403 | 0.020 |
Why?
|
| Consumer Behavior | 1 | 1991 | 70 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 386 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1991 | 70 | 0.020 |
Why?
|
| Leukemia | 1 | 1993 | 245 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 539 | 0.020 |
Why?
|
| Automation, Laboratory | 1 | 2010 | 7 | 0.020 |
Why?
|
| X-Rays | 1 | 2010 | 31 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1991 | 131 | 0.020 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 1989 | 8 | 0.020 |
Why?
|
| Torsion, Mechanical | 1 | 2009 | 5 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 250 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 91 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 259 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 528 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1993 | 306 | 0.020 |
Why?
|
| Medication Errors | 1 | 2009 | 83 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2007 | 1103 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 286 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 167 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 151 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 177 | 0.020 |
Why?
|
| Europe | 1 | 2009 | 416 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 3888 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2003 | 2033 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 6456 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2007 | 40 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 439 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1003 | 0.020 |
Why?
|
| Veins | 1 | 2007 | 68 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 555 | 0.020 |
Why?
|
| Life Tables | 1 | 2006 | 21 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 351 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2009 | 845 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1986 | 136 | 0.010 |
Why?
|
| Drug Implants | 1 | 2006 | 83 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2010 | 949 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 74 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 183 | 0.010 |
Why?
|
| Artifacts | 1 | 2006 | 142 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 514 | 0.010 |
Why?
|
| Aorta | 1 | 2007 | 431 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 1031 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 312 | 0.010 |
Why?
|
| Streptokinase | 2 | 1998 | 9 | 0.010 |
Why?
|
| Diabetes Insipidus | 1 | 1983 | 6 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 2004 | 76 | 0.010 |
Why?
|
| Sputum | 1 | 2006 | 308 | 0.010 |
Why?
|
| Hospitalization | 2 | 2006 | 2443 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 216 | 0.010 |
Why?
|
| Pain | 1 | 2009 | 784 | 0.010 |
Why?
|
| Sound | 1 | 1983 | 55 | 0.010 |
Why?
|
| Technology | 1 | 1983 | 96 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2003 | 59 | 0.010 |
Why?
|
| Critical Illness | 1 | 2009 | 893 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 116 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1968 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 782 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 378 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 2002 | 283 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2002 | 494 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 770 | 0.010 |
Why?
|
| Exercise | 1 | 1989 | 2206 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1997 | 72 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1814 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 356 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 1994 | 15 | 0.010 |
Why?
|
| Traction | 1 | 1994 | 19 | 0.010 |
Why?
|
| Femoral Vein | 1 | 1994 | 38 | 0.010 |
Why?
|
| Staphylococcus epidermidis | 1 | 1994 | 79 | 0.010 |
Why?
|
| Steroids | 1 | 1994 | 160 | 0.010 |
Why?
|
| Cytarabine | 1 | 1993 | 66 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1993 | 53 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1993 | 191 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1993 | 153 | 0.010 |
Why?
|
| Vincristine | 1 | 1993 | 141 | 0.010 |
Why?
|
| Adolescent | 3 | 1998 | 22507 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1997 | 1894 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 920 | 0.010 |
Why?
|
| Atrioventricular Node | 1 | 1990 | 15 | 0.010 |
Why?
|
| Body Constitution | 1 | 1990 | 51 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1993 | 398 | 0.000 |
Why?
|
| Staphylococcal Infections | 1 | 1994 | 391 | 0.000 |
Why?
|
| Respiration | 1 | 1990 | 207 | 0.000 |
Why?
|
| Dizziness | 1 | 1990 | 101 | 0.000 |
Why?
|
| Syndrome | 1 | 1990 | 380 | 0.000 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1988 | 2 | 0.000 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 1988 | 5 | 0.000 |
Why?
|
| Dyspnea | 1 | 1990 | 251 | 0.000 |
Why?
|
| Fatigue | 1 | 1990 | 366 | 0.000 |
Why?
|
| Tromethamine | 1 | 1986 | 2 | 0.000 |
Why?
|
| Citrates | 1 | 1986 | 41 | 0.000 |
Why?
|
| Potassium Chloride | 1 | 1986 | 40 | 0.000 |
Why?
|
| Heart Arrest, Induced | 1 | 1986 | 34 | 0.000 |
Why?
|
| Glutamates | 1 | 1986 | 66 | 0.000 |
Why?
|
| Citric Acid | 1 | 1986 | 34 | 0.000 |
Why?
|
| Protein Binding | 1 | 1993 | 2283 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1986 | 88 | 0.000 |
Why?
|
| Phosphates | 1 | 1986 | 180 | 0.000 |
Why?
|
| Glutamic Acid | 1 | 1986 | 251 | 0.000 |
Why?
|
| Diuresis | 1 | 1983 | 10 | 0.000 |
Why?
|
| Arginine Vasopressin | 1 | 1983 | 44 | 0.000 |
Why?
|
| Vasopressins | 1 | 1983 | 60 | 0.000 |
Why?
|
| Anxiety | 1 | 1990 | 1113 | 0.000 |
Why?
|
| Heart | 1 | 1986 | 636 | 0.000 |
Why?
|
| Glucose | 1 | 1986 | 1049 | 0.000 |
Why?
|
| Surveys and Questionnaires | 1 | 1990 | 6079 | 0.000 |
Why?
|